Aptevo Therapeutics Inc.APVO
Price (close)
$1.89
Market cap
$2.7M
P/E
—
Revenue (TTM)
—
Net income
-$26.4M
Dividend yield
—
1-year total return
-93.4%
Net margin
—
Revenue growth
—
Debt / equity
—
What Aptevo Therapeutics Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $4.3M | $12.3M | $3.1M | — | — | — |
| Net income | -$17.8M | -$28.5M | $8.0M | -$17.4M | -$24.1M | -$26.0M |
| Free cash flow | -$29.4M | -$22.4M | -$21.1M | — | — | — |
More on APVO.
- Aptevo Therapeutics Inc. summary
- Aptevo Therapeutics Inc. financial statements
- Aptevo Therapeutics Inc. key metrics
- Aptevo Therapeutics Inc. health scores and style box
- Aptevo Therapeutics Inc. earnings
- Aptevo Therapeutics Inc. dividends
- Aptevo Therapeutics Inc. valuation
- Aptevo Therapeutics Inc. ownership and insiders
- Aptevo Therapeutics Inc. peers
Figures from Aptevo Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.